Back to Search
Start Over
Efficacy, Safety, and Strategies for Recombinant-Activated Factor VII in Cardiac Surgical Bleeding: A Narrative Review
- Source :
- Journal of cardiothoracic and vascular anesthesia. 36(4)
- Publication Year :
- 2021
-
Abstract
- As perioperative bleeding continues to be a major source of morbidity and mortality in cardiac surgery, the search continues for an ideal hemostatic agent for use in this patient population. Transfusion of blood products has been associated both with increased costs and risks, such as infection, prolonged mechanical ventilation, increased length of stay, and decreased survival. Recombinant-activated factor VII (rFVIIa) first was approved for the US market in 1999 and since that time has been used in a variety of clinical settings. This review summarizes the existing literature pertaining to perioperative rFVIIa, in addition to society recommendations and current guidelines regarding its use in cardiac surgery.
- Subjects :
- medicine.medical_specialty
medicine.medical_treatment
Blood Loss, Surgical
Factor VIIa
Postoperative Hemorrhage
chemistry.chemical_compound
medicine
Extracorporeal membrane oxygenation
Humans
Cardiac Surgical Procedures
Intensive care medicine
Retrospective Studies
Mechanical ventilation
Hemostatic Agent
biology
Factor VII
business.industry
Perioperative
medicine.disease
Thrombosis
Recombinant Proteins
Cardiac surgery
Anesthesiology and Pain Medicine
chemistry
Recombinant factor VIIa
biology.protein
Cardiology and Cardiovascular Medicine
business
Subjects
Details
- ISSN :
- 15328422
- Volume :
- 36
- Issue :
- 4
- Database :
- OpenAIRE
- Journal :
- Journal of cardiothoracic and vascular anesthesia
- Accession number :
- edsair.doi.dedup.....5ab956c057fcf636e5b251535a20de26